文献速递慢阻肺

非急性加重慢阻肺患者的死亡率:英国初级保健数据纵向分析

Mortality in non-exacerbating COPD: a longitudinal analysis of UK primary care data.
PubMed 文献 · Thorax · 2022-11-24

基于英国初级保健数据,研究比较非急性加重与急性加重慢阻肺患者的特征和死亡率。

要点

  • 非急性加重慢阻肺患者全因死亡风险低于急性加重者,首年HR 0.62,之后HR 0.87。
  • 非急性加重者呼吸系统死亡占比29.2%,低于急性加重者的40.3%。
  • 非急性加重者恶性肿瘤和心血管死亡占比更高,三类死因占比相近。

核心结论

  • 在初级保健队列中,非急性加重慢阻肺患者具有独特临床特征且死亡率较低。
  • 非急性加重者死于呼吸系统、恶性肿瘤或心血管疾病的可能性相当。

研究设计与样本

  • 使用英国临床实践研究数据链、医院统计和国家统计局2004年至2018年数据。
  • 采用Cox回归比较总死亡率,竞争风险分析比较病因别死亡率,并调整年龄、性别、贫困、吸烟状态、BMI、GOLD分期和合并症。

主要发现

  • 17.3%的患者在3年基线期内未发生急性加重,平均随访4年。
  • 非急性加重者男性比例更高(63.3% vs 52.4%,p<0.001),哮喘史比例更低(33.9% vs 43.6%,p<0.001),FEV1<50%预计值比例更低(23.7% vs 31.8%)。
  • 非急性加重者较急性加重者全因死亡调整HR在随访第一年为0.62(95% CI 0.56-0.70),此后为0.87(95% CI 0.83-0.91)。
  • 非急性加重者呼吸系统死亡占比29.2%,低于急性加重者的40.3%;恶性肿瘤死亡占比29.4% vs 23.4%,心血管疾病死亡占比26.2% vs 22.9%。
  • 随访第一年后,恶性肿瘤和循环系统死亡的HR升高。

临床怎么用

  • 对非急性加重慢阻肺患者应关注恶性肿瘤和心血管疾病的预防与筛查。
  • 非急性加重表型死亡风险仍较高,需长期随访管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Non-exacerbating patients with chronic obstructive pulmonary disease (COPD) are a less studied phenotype. We investigated clinical characteristics, mortality rates and causes of death among non-exacerbating compared with exacerbating patients with COPD. METHODS: We used data from the Clinical Practice Research Datalink, Hospital Episode Statistics and Office for National Statistics between 1 January 2004 and 31 December 2018. Ever smokers with a COPD diagnosis with minimum 3 years of baseline information were included. We compared overall using Cox regression and cause-specific mortality rates using competing risk analysis, adjusted for age, sex, deprivation, smoking status, body mass index, GOLD stage and comorbidities. Causes of death were identified using International Classification of Diseases-10 codes. RESULTS: Among 67 516 patients, 17.3% did not exacerbate during the 3-year baseline period. Mean follow-up was 4 years. Non-exacerbators were more likely to be male (63.3% vs 52.4%, p<0.001) and less often had a history of asthma (33.9% vs 43.6%, p<0.001) or FEV1<50% predicted (23.7 vs 31.8%) compared with exacerbators. Adjusted HR for overall mortality in non-exacerbators compared with exacerbators was 0.62 (95% CI 0.56 to 0.70) in the first year of follow-up and 0.87 (95% CI 0.83 to 0.91) thereafter. Non-exacerbating patients with COPD died less of respiratory causes than exacerbators (29.2% vs 40.3%) and more of malignancies (29.4% vs 23.4%) and cardiovascular diseases (26.2% vs 22.9%). HRs for malignant and circulatory causes of death were increased after the first year of follow-up. DISCUSSION: In this primary care cohort, non-exacerbators showed distinct clinical characteristics and lower mortality rates. Non-exacerbators were equally likely to die of respiratory, malignant or cardiovascular diseases.

来源:Thorax,查看原文。版权归原作者所有。

引用

  1. Lenoir A, Whittaker H, Gayle A, et al. Mortality in non-exacerbating COPD: a longitudinal analysis of UK primary care data. Thorax. 2022. PMID: 36423926. doi:10.1136/thorax-2022-218724

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。